Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction

Rafael Harari; Usman Baber

doi:10.1016/j.iccl.2016.06.007

Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction

Interv Cardiol Clin. 2016 Oct;5(4):481-495. doi: 10.1016/j.iccl.2016.06.007. Epub 2016 Aug 12.

Authors

Rafael Harari¹, Usman Baber²

Affiliations

¹ Department of Cardiology, The Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029-6574, USA.
² Department of Cardiology, The Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029-6574, USA. Electronic address: usman.baber@mountsinai.org.

PMID: 28581997
DOI: 10.1016/j.iccl.2016.06.007

Abstract

Cardiovascular disease is the leading cause of death worldwide. Case-fatality rates for myocardial infarction (MI) in the United States have decreased over the past decades, in large part due to advances in the treatment of acute MI and secondary preventive therapy after MI. Antiplatelet therapy remains the cornerstone of treatment of MI. This article reviews the current state of antiplatelet therapy in ST-segment elevation MI.

Keywords: Antiplatelet agents; GP IIb/IIIa inhibitors; P2Y(12) inhibitors; ST-segment elevation myocardial infarction; STEMI.

Publication types

Review

MeSH terms

Humans
Platelet Aggregation Inhibitors / therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
ST Elevation Myocardial Infarction / drug therapy*
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex